Investor Presentaiton

Investor presentation Full year 2018 Slide 39 Pipeline supports significant growth opportunities across all four strategic focus areas PHASE 1 NN1535 LAIsema NN9023 - OG2023SC NN9838 Amylin AM833 NN9747 PYY 1562 analogue NN9277- -GG-co-agonist NN9423 Tri-agonist 1706 NN9775 PYY 1875 analogue NN7533 Eclipse PHASE 2 NN1436 - LAI287 Anti-IL-21 and liraglutide Concizumab Somapacitan - QW GHD1 Semaglutide NASH PHASE 3 Oral semaglutide Semaglutide obesity SUBMITTED APPROVED N8-GP - Long-acting rFVIII LevemirⓇ Somapacitan - QW AGHD2 NovoRapidⓇ NovoMix® Tresiba® RyzodegⓇ XultophyⓇ Victoza® FiaspⓇ OzempicⓇ SaxendaⓇ NovoSevenⓇ NovoEight® NovoThirteenⓇ RebinynⓇ/RefixiaⓇ3 NorditropinⓇ Diabetes Obesity Haemophilia Growth disorders Other serious chronic diseases 1 Study conducted in growth hormone disorders; 2 Study conducted in adult growth hormone disorder; 3 Refixia® is the global brand name and RebinynⓇ is the brand name in North America QW: Once-weekly; GG: Glucagon GLP-1; Sc: Subcutaneous; QD: Once-daily changing diabetes novo nordisk

View entire presentation